A multicenter, retrospective, observational study of the clinical outcomes and risk factors for relapse of ulcerative colitis at 1 year after leukocytapheresis
Authors:
Open Access
- 8 June 2017
- journal article
- research article
- Published by Springer Nature in Journal of Gastroenterology
- Vol. 53 (3) , 387-396
Abstract
Background Extracorporeal leukocytapheresis (LCAP) is effective for inducing remission of ulcerative colitis (UC). This retrospective observational study aimed to evaluate the clinical outcome at 1 year and identify risk factors for relapse of UC after LCAP. Methods Patients with active UC treated with LCAP between 2010 and 2012 were enrolled from 54 medical facilities in Japan. Clinical data evaluated at 1 year after the last LCAP session included the incidence of relapse, 1-year cumulative relapse-free rate, risk factors for relapse, and history of re-induction treatment following relapse. Relapse was defined by the addition of treatment to induce remission. The primary endpoint was the 1-year cumulative relapse-free rate. Secondary endpoints were risk factors for relapse and outcomes of re-induction treatment after relapse. Results For 314 patients, the 1-year cumulative relapse-free rate was 63.6%. Following LCAP, a Lichtiger clinical activity index (CAI) of 3 or 4 and high leukocyte count (cut-off value: 7790/mm3) were associated with a greater risk of relapse. Intensive LCAP (≥4 sessions within the first 2 weeks) was associated with favorable long-term outcomes in corticosteroid-refractory patients. The response rate was 85.1% among 30 patients who required re-treatment with LCAP. Conclusions The majority of patients (>60%) with UC treated with LCAP achieved clinical remission within 1 year and remained relapse-free. A higher Lichtiger CAI and leukocyte count following LCAP were risk factors for relapse. Re-induction therapy with LCAP was effective for relapse of UC.Keywords
Funding Information
- Asahi Kasei Medical Co. Ltd.
This publication has 25 references indexed in Scilit:
- A Panel to Predict Long-term Outcome of Infliximab Therapy for Patients With Ulcerative ColitisClinical Gastroenterology and Hepatology, 2015
- Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitisJournal of Gastroenterology, 2013
- Long-term prognosis of patients with ulcerative colitis treated with cytapheresis therapyJournal of Crohn's and Colitis, 2013
- Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitisInflammatory Bowel Diseases, 2012
- From Randomized Controlled Trials to Observational StudiesThe American Journal of Medicine, 2009
- Modulation of platelet aggregation responses by leukocytapheresis therapy in patients with active ulcerative colitisJournal of Gastroenterology, 2006
- Activated platelets as a possible early marker to predict clinical efficacy of leukocytapheresis in severe ulcerative colitis patientsJournal of Gastroenterology, 2006
- Leukocytapheresis therapy, performed with leukocyte removal filter, for inflammatory bowel diseaseJournal of Gastroenterology, 1995
- 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitisGastroenterology, 1987
- Corticotropin versus hydrocortisone in the intravenous treatment of ulcerative colitisGastroenterology, 1983